कनाडा - फ़्रेंच - Health Canada

abbvie corporation - ombitasvir; ritonavir; paritaprévir; dasabuvir (dasabuvir sodique monohydraté) - trousse - 12.5mg; 50mg; 75mg; 250mg - ombitasvir 12.5mg; ritonavir 50mg; paritaprévir 75mg; dasabuvir (dasabuvir sodique monohydraté) 250mg - inhibiteurs de la polymérase du virus de l'hépatite c

कनाडा - फ़्रेंच - Health Canada

abbvie corporation - ombitasvir; paritaprévir; ritonavir - comprimé - 12.5mg; 75mg; 50mg - ombitasvir 12.5mg; paritaprévir 75mg; ritonavir 50mg - inhibiteurs de la protéase du virus de l'hépatite c

यूरोपीय संघ - फ़्रेंच - EMA (European Medicines Agency)

janssen-cilag international nv - darunavir - infections au vih - antiviraux à usage systémique - prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adult and paediatric patients from the age of 3 years and at least 15 kg body weight. prezista, co administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg). in deciding to initiate treatment with prezista co administered with cobicistat or low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. genotypic or phenotypic testing (when available) and treatment history should guide the use of prezista. prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (hiv 1) infection. prezista 75 mg, 150 mg, and 600 mg tablets may be used to provide suitable dose regimens:for the treatment of hiv 1 infection in antiretroviral treatment (art) experienced adult patients, including those that have been highly pre treated. for the treatment of hiv 1 infection in paediatric patients from the age of 3 years and at least 15 kg body weight. in deciding to initiate treatment with prezista co administered with low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. genotypic or phenotypic testing (when available) and treatment history should guide the use of prezista. prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (hiv 1) infection. prezista, co administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg). prezista 400 mg and 800 mg tablets may be used to provide suitable dose regimens for the treatment of hiv 1 infection in adult and paediatric patients from the age of 3 years and at least 40 kg body weight who are:antiretroviral therapy (art) naïve. art experienced with no darunavir resistance associated mutations (drv rams) and who have plasma hiv 1 rna < 100,000 copies/ml and cd4+ cell count ≥ 100 cells x 106/l. in deciding to initiate treatment with prezista in such art experienced patients, genotypic testing should guide the use of prezista.

यूरोपीय संघ - फ़्रेंच - EMA (European Medicines Agency)

janssen-cilag international nv - l'étravirine - infections au vih - non-nucleoside reverse transcriptase inhibitors, antivirals for systemic use - intelence, en combinaison avec un inhibiteur de la protéase boosté et d’autres médicaments antirétroviraux, est indiqué pour le traitement des infections humaines-immunodéficience-virus-type-1 (vih-1) chez les patients adultes antirétroviral-traitement-expérimentés et chez les patients pédiatriques antirétroviral-traitement-connu depuis six ans. cette indication est fondée sur une semaine 48 analyses de deux essais de phase iii des essais dans de très patients prétraités où intelence a été étudiée en combinaison avec un fond optimisé régime (obr) qui inclus darunavir/ritonavir. l'indication chez les patients pédiatriques est basée sur 48 semaines analyses d'un seul bras, la phase ii de l'essai dans antirétroviral, le traitement connu pour les patients pédiatriques.

कनाडा - फ़्रेंच - Health Canada

pharmascience inc - atorvastatine (atorvastatine calcique) - comprimé - 10mg - atorvastatine (atorvastatine calcique) 10mg - hmg-coa reductase inhibitors

कनाडा - फ़्रेंच - Health Canada

pharmascience inc - atorvastatine (atorvastatine calcique) - comprimé - 20mg - atorvastatine (atorvastatine calcique) 20mg - hmg-coa reductase inhibitors

कनाडा - फ़्रेंच - Health Canada

pharmascience inc - atorvastatine (atorvastatine calcique) - comprimé - 40mg - atorvastatine (atorvastatine calcique) 40mg - hmg-coa reductase inhibitors

कनाडा - फ़्रेंच - Health Canada

pharmascience inc - atorvastatine (atorvastatine calcique) - comprimé - 80mg - atorvastatine (atorvastatine calcique) 80mg - hmg-coa reductase inhibitors

कनाडा - फ़्रेंच - Health Canada

teva canada limited - atorvastatine (atorvastatine calcique) - comprimé - 10mg - atorvastatine (atorvastatine calcique) 10mg - hmg-coa reductase inhibitors

कनाडा - फ़्रेंच - Health Canada

teva canada limited - atorvastatine (atorvastatine calcique) - comprimé - 20mg - atorvastatine (atorvastatine calcique) 20mg - hmg-coa reductase inhibitors